1例脓毒血症继发肺曲霉菌感染患者的药学监护

doi:10.19803/j.1672-8629.20240365

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 1064-1067.
DOI: 10.19803/j.1672-8629.20240365

1例脓毒血症继发肺曲霉菌感染患者的药学监护

张彩霞¹, 周易^1,*, 谭璐¹, 陈文明¹, 柳阳², 游禹³

¹长江大学附属黄冈市中心医院药学部,湖北黄冈 438000;
²湖北中医药大学附属湖北省中医院药事部,湖北武汉 430000;
³武穴市中医医院药剂科,湖北武穴 435400

收稿日期:2024-05-31 出版日期:2024-09-15 发布日期:2024-09-14
通讯作者: ^*周易,男,硕士,副主任药师,临床药学与药理学。E-mail:zy915901@163.com
作者简介:张彩霞,女,硕士,主管药师,临床药学。

Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis

ZHANG Caixia¹, ZHOU Yi^1,*, TAN Lu¹, CHEN Wenming¹, LIU Yang², YOU Yu³

¹Department of Pharmacy, Huanggang Central Hospital of Yangtze University, Huanggang Hubei 438000, China;
²Department of Pharmacy, Hubei Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Chinese Medicine, Wuhan Hubei 430000, China;
³Department of Pharmacy, Wuxue Hospital of Traditional Chinese Medicine,Wuxue Hubei 435400, China

Received:2024-05-31 Online:2024-09-15 Published:2024-09-14

摘要/Abstract

摘要： 目的探讨临床药师在抗感染治疗过程中的作用,为临床提供药学监护与个体化治疗积累实践经验,促进临床合理用药。方法临床药师参与1例脓毒血症继发肺曲霉菌感染患者的抗感染治疗全过程。协助临床医师制定和调整治疗方案,对伏立康唑片进行血药浓度监测并提供个体化给药方案及药学监护。结果患者病情得到好转,为以后提供更好的药学服务积累了经验。结论临床药师积极参与脓毒血症继发肺曲霉菌感染的药物治疗实践,保证了患者药物治疗的有效性及安全性,充分体现了临床药师的自身价值。

关键词: 脓毒血症, 烟曲霉菌, 伏立康唑片, 血药浓度监测, 药学监护, 临床药师

Abstract: Objective To explore the role of clinical pharmacists in the course of anti-infection treatment, and exchange experience related to individualized treatment of patients with pulmonary aspergillus infection secondary to sepsis so as to promote clinical rational drug use. Methods Clinical pharmacists participated in the whole process of anti-infection treatment of a patient with pulmonary aspergillus infection secondary to sepsis by assisting clinicians in formulating and adjusting treatment plans, monitoring voriconazole concentrations in blood, and providing individualized medications and pharmaceutical care. Results The condition of the patient was improved eventually, which offered experience for providing better pharmaceutical care in the future. Conclusion Clinical pharmacists' participation in medications against pulmonary aspergillus infection secondary to sepsis can help ensure the effectiveness and safety of drug treatment for patients so that the worth of clinical pharmacists can be proved.

Key words: sepsis, pulmonary aspergillo, voriconazole, tablrt, monitoring of plasma concentrations, pharmaceutical care, clinical pharmacist

中图分类号:

R994.11

张彩霞, 周易, 谭璐, 陈文明, 柳阳, 游禹. 1例脓毒血症继发肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2024, 21(9): 1064-1067.

ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu. Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240365

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/1064

参考文献

[1] XIAO YL, JIANG T.Prevention and treatment of invasive pulmonary aspergillosis[J].Medical Information(医学信息), 2021, 34(6): 43-46.
[2] BARAC A,KOSMIDIS C,ALASTRUEY-IZQUIERDO A,et al.Chronic pulmonary aspergillosis update: a year in review[J].Med Mycol, 2019, 57(Suppl 2): 104-109.
[3] WANG BB,XU XQ,TAN R,et al.Monitoring and analysis of voriconazole concentration in 73 patients with pulmonary aspergillus[J].Chinese Journal of New Medicine and Clinical Medicine(中国新药与临床杂志), 2022, 41(4): 228-233.
[4] BUPHA-INTR O,BUTTERS C,REYNOLDS G.Australasian antifungal guidelines steering committee. consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than aspergillus in the haematology/oncology setting, 2021[J]. Intern Med J, 2021, 51(Suppl 7): 177-219.
[5] CHEN F,HU SL,LIU JM,et al.A real-world study of voriconazole associated liver injury[J].Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(19): 2006-2010.
[6] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association. Chinese guidelines for diagnosis and management of drug - induced liver injury (2023 version)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2023, 31(4): 355-384.
[7] Emergency Physicians Branch of Chinese Medical Doctor Association, Shock and Sepsis Professional Committee of Chinese Society of Research Hospitals. Guidelines for emergency treatment of sepsis/septic shock in China (2018)[J].Infection, Inflammation, Repair,2019, 20(1): 3-22.
[8] PAUL M,CARRARA E,RETAMAR P.European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)[J]. Clin Microbiol Infect, 2022, 28(4): 521-547.
[9] GILBERT DN,CHAMBERS HF,ELIOPOULOS GM,et al.Sanford’s Antimicrobial Guide[M]. 48th edition. Beijing:China Union Medical College Press, 2018: 224-225.
[10] CHEN T, YANG Y, SHANG XY, et al.Analysis of risk factors and drug resistance of enterococcus faecium infection in intensive care unit[J]. Journal of PLA Medical College(解放军医学院学报), 2023, 44(6): 650-654.
[11] Clinical Microbiology Branch, China Association for the Promotion of International Exchanges in Healthcare, Clinical Microbiology Group, Laboratory Medicine Branch, Chinese Medical Association, Microbiology and Immunology Branch, Chinese Medical Association. Guidelines for mycological examination of invasive mycosis[J]. Chinese Journal of Laboratory Medicine(中华检验医学杂志), 2023, 46(6): 541-557.
[12] LIU X,LI YH,SONG CC.The value of bronchoalveolar lavage fluid G test, GM test and serum galactomannan test in early diagnosis of invasive pulmonary aspergillus infection[J]. Journal of Experimental and Laboratory Medicine(实验与检验医学), 2023, 41(3): 277-279.
[13] Branch of Hematology, Chinese Medical Doctor Association, Chinese Working Group on Invasive Fungal Infections. Diagnostic criteria and therapeutic principles of invasive mycosis in patients with hematological diseases/malignancies(中华内科杂志), 2020, 59(10): 754-763.
[14] Expert Consensus Group on the use of procalcitonin in the graded management of lower respiratory tract infectious diseases in adults. Expert consensus on the application of procalcitonin in the graded management of adult lower respiratory tract infectious diseases[J]. Chinese Journal of Emergency Medicine(中华急诊医学杂志), 2021, 30(4): 393-401.
[15] Working Group on revision of Guidelines for Clinical Use of Antimicrobial Agents. Guiding Principles for Clinical Application of Antibiotics[M]. 2015 edition. Beijing: People’s Medical Publishing House, 2015: 13-14.
[16] SHI WX, YIE XF, CAI YY, et al.Analysis of voriconazole administration interval and dose in antifungal therapy of pulmonary aspergillus disease patients[J].Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2020, 29(3): 223-226.
[17] WANG XB,LIU TT,CHEN DH.Monitoring and analysis of individual voriconazole use in adults[J]. Journal of Chongqing Medical University(重庆医科大学学报), 2023, 48(6): 721-725.
[18] HANG XY, WANG M, SONG XL.Analysis of 60 cases of voriconazole concentration monitoring in hematology department[J].Drug Evaluation(药品评价), 2022, 19(10): 595-598.
[19] WU AL.Effect of hypoproteinemia on antifungal efficacy and valley concentration of voriconazole[D]. Anhui : Anhui Medical University(安徽医科大学), 2022.
[20] AKESUE Y, HANAI Y, ODA K.Japanese antimicrobial therapeutic drug monitoring guideline committee, clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients:consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. Clin Ther, 2022, 44(12): 1604-1623.

1例脓毒血症继发肺曲霉菌感染患者的药学监护

Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	严妍, 刘乃一, 乔玲, 张毅, 杨晨. 别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析[J]. 中国药物警戒, 2024, 21(9): 1068-1070.
[2]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[3]	林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.
[4]	徐钰行, 弓清梅, 骆宇琛, 王宗隅, 张囝. 膀胱内灌注卡介苗致多器官功能衰竭1例分析[J]. 中国药物警戒, 2024, 21(6): 697-699.
[5]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[6]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[7]	吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.
[8]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[9]	沈江华, 孔超, 潘福敏, 褚燕琦. 1例贝纳柯克斯体椎体骨髓炎患者的药学监护[J]. 中国药物警戒, 2024, 21(10): 1166-1168.
[10]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[11]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[12]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[13]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[14]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[15]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.